{"nctId":"NCT03481634","briefTitle":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","startDateStruct":{"date":"2018-07-23","type":"ACTUAL"},"conditions":["Diabetic Macular Edema"],"count":566,"armGroups":[{"label":"Brolucizumab 3 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Brolucizumab"]},{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Brolucizumab"]},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aflibercept"]}],"interventions":[{"name":"Brolucizumab","otherNames":["RTH258","ESBA1008"]},{"name":"Aflibercept","otherNames":["Eylea"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent before any assessment\n* Patients with type 1 or type 2 diabetes mellitus and HbA1c of ≤10% at screening\n* Medication for the management of diabetes stable within 3 months prior to randomization and is expected to remain stable during the course of the study\n\nExclusion Criteria:\n\n* Active proliferative diabetic retinopathy in the study eye\n* Active intraocular or periocular infection or active intraocular inflammation in study eye\n* Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \\> 25 millimeters mercury (mmHg)\n* Previous treatment with anti-VEGF drugs or investigational drugs in the study eye\n* Stroke or myocardial infarction during the 6-month period prior to baseline\n* Uncontrolled blood pressure defined as a systolic value ≥160 mmHg or diastolic value ≥100 mmHg\n\nOther protocol-specified inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 78 to 23 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.\n\nThis endpoint was analyzed via the pairwise ANOVA method where the 2 dose groups of Brolucizumab are compared to Aflibercept.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"0.66"},{"groupId":"OG002","value":"10.6","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"9.2","spread":"0.57"},{"groupId":"OG002","value":"10.5","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in BCVA Over the Period Week 40 Through Week 52","description":"BCVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 78 to 23 (per the inclusion criteria) (approximate Snellen equivalent of 20/32 to 20/320) in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.\n\nThis endpoint was analyzed via the pairwise ANOVA method where the 2 dose groups of Brolucizumab are compared to Aflibercept.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"0.63"},{"groupId":"OG002","value":"10.5","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"9.0","spread":"0.53"},{"groupId":"OG002","value":"10.5","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Patients Maintained at q12w - Probability of Maintaining on q12w","description":"Positive treatment status is defined as intravitreal (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\]. This outcome measure is pre-specified for brolucizumab treatment arms only.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.758","spread":null},{"groupId":"OG001","value":"0.807","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.545","spread":null},{"groupId":"OG001","value":"0.628","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.474","spread":null},{"groupId":"OG001","value":"0.550","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients Maintained at q12w (for Those Patients Who Qualified for q12w at Week 36) - Probability of Maintaining on q12w","description":"Positive treatment status is defined as intravitreal (IVT) injections per planned dosing regimen \\[every 8 weeks (q8w)\\]. This outcome measure is pre-specified for brolucizumab treatment arms only.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.870","spread":null},{"groupId":"OG001","value":"0.876","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA at Each Visit up to Week 52","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 78 to 23 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"5.02"},{"groupId":"OG001","value":"4.5","spread":"5.22"},{"groupId":"OG002","value":"5.1","spread":"6.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"5.86"},{"groupId":"OG001","value":"6.0","spread":"6.22"},{"groupId":"OG002","value":"6.8","spread":"6.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"5.90"},{"groupId":"OG001","value":"6.6","spread":"6.54"},{"groupId":"OG002","value":"7.1","spread":"7.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"5.93"},{"groupId":"OG001","value":"7.3","spread":"6.57"},{"groupId":"OG002","value":"8.1","spread":"7.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"7.00"},{"groupId":"OG001","value":"7.5","spread":"6.83"},{"groupId":"OG002","value":"8.5","spread":"7.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"6.35"},{"groupId":"OG001","value":"8.0","spread":"6.84"},{"groupId":"OG002","value":"8.8","spread":"7.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"7.59"},{"groupId":"OG001","value":"8.3","spread":"7.51"},{"groupId":"OG002","value":"9.8","spread":"7.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"6.42"},{"groupId":"OG001","value":"9.3","spread":"7.08"},{"groupId":"OG002","value":"9.2","spread":"7.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"6.58"},{"groupId":"OG001","value":"9.6","spread":"7.40"},{"groupId":"OG002","value":"10.3","spread":"7.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"7.76"},{"groupId":"OG001","value":"9.2","spread":"7.20"},{"groupId":"OG002","value":"9.9","spread":"7.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"8.10"},{"groupId":"OG001","value":"8.6","spread":"8.15"},{"groupId":"OG002","value":"10.2","spread":"7.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"10.47"},{"groupId":"OG001","value":"9.5","spread":"7.99"},{"groupId":"OG002","value":"10.0","spread":"8.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"10.92"},{"groupId":"OG001","value":"9.6","spread":"7.66"},{"groupId":"OG002","value":"10.7","spread":"8.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"11.53"},{"groupId":"OG001","value":"10.0","spread":"7.63"},{"groupId":"OG002","value":"11.1","spread":"8.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"10.72"},{"groupId":"OG001","value":"10.2","spread":"7.66"},{"groupId":"OG002","value":"10.7","spread":"8.87"}]}]}]},{"type":"SECONDARY","title":"BCVA (Letters Read): ANOVA Results for Average Change From Baseline Over the Period Week 88 Through Week 100 for the Study Eye (FAS - LOCF)","description":"Visual acuity was assessed at every study visit using best correction determined from protocol refraction (BCVA). BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts.\n\nLS Mean estimates are reported, comparing the 2 Brolucizumab arms to Aflibercept. Results do not apply to the Brolucizumab 6 mg arm when Brolucizumab 3mg is compared to Aflibercept. Likewise, results do not apply to the Brolucizumab 3 mg arm when Brolucizumab 6 mg is compared to Aflibercept.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.77"},{"groupId":"OG002","value":"10.6","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"8.6","spread":"0.72"},{"groupId":"OG002","value":"10.6","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Patients Maintained at q12w up to Week 64 (After Three q12w- Treatment Intervals) and Week 100 - Probability of Maintaining on q12w","description":"This outcome measure is pre-specified for brolucizumab treatment arms only","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.758","spread":null},{"groupId":"OG001","value":"0.807","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.545","spread":null},{"groupId":"OG001","value":"0.628","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.474","spread":null},{"groupId":"OG001","value":"0.550","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.403","spread":null},{"groupId":"OG001","value":"0.520","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.394","spread":null},{"groupId":"OG001","value":"0.487","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.365","spread":null},{"groupId":"OG001","value":"0.460","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.334","spread":null},{"groupId":"OG001","value":"0.441","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary: Patients Maintained at q12w up to Week 64 (After Three q12w- Treatment Intervals) and Week 100, Within Those Patients That Qualified for q12w at Week 36 - Probability of Maintaining on q12w","description":"This outcome measure is pre-specified for brolucizumab treatment arms only","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.870","spread":null},{"groupId":"OG001","value":"0.876","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.740","spread":null},{"groupId":"OG001","value":"0.828","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.723","spread":null},{"groupId":"OG001","value":"0.775","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.670","spread":null},{"groupId":"OG001","value":"0.732","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.613","spread":null},{"groupId":"OG001","value":"0.702","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Subfield Thickness (CSFT) at Each Visit up to Week 52 - Pairwise ANOVA Results","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.\n\nLS Mean estimates are reported, comparing the 2 Brolucizumab arms to Aflibercept. Results do not apply to the Brolucizumab 6 mg arm when Brolucizumab 3mg is compared to Aflibercept. Likewise, results do not apply to the Brolucizumab 3 mg arm when Brolucizumab 6 mg is compared to Aflibercept.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-104.7","spread":"6.11"},{"groupId":"OG002","value":"-104.1","spread":"6.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-105.6","spread":"5.92"},{"groupId":"OG002","value":"-103.4","spread":"5.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-107.1","spread":"6.24"},{"groupId":"OG002","value":"-119.3","spread":"6.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-116.1","spread":"5.89"},{"groupId":"OG002","value":"-118.6","spread":"5.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-125.1","spread":"6.06"},{"groupId":"OG002","value":"-126.1","spread":"6.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-128.9","spread":"5.82"},{"groupId":"OG002","value":"-125.6","spread":"5.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-131.0","spread":"6.14"},{"groupId":"OG002","value":"-137.4","spread":"6.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-134.5","spread":"6.22"},{"groupId":"OG002","value":"-137.3","spread":"6.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-142.3","spread":"5.98"},{"groupId":"OG002","value":"-143.3","spread":"6.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-146.5","spread":"5.83"},{"groupId":"OG002","value":"-143.1","spread":"5.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-138.1","spread":"6.27"},{"groupId":"OG002","value":"-147.0","spread":"6.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-144.2","spread":"5.96"},{"groupId":"OG002","value":"-146.8","spread":"5.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-151.8","spread":"6.01"},{"groupId":"OG002","value":"-148.3","spread":"6.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-153.8","spread":"5.71"},{"groupId":"OG002","value":"-148.0","spread":"5.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-152.6","spread":"6.37"},{"groupId":"OG002","value":"-138.7","spread":"6.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-156.2","spread":"6.30"},{"groupId":"OG002","value":"-138.4","spread":"6.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-163.4","spread":"5.81"},{"groupId":"OG002","value":"-154.6","spread":"5.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-163.3","spread":"5.97"},{"groupId":"OG002","value":"-154.6","spread":"6.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-147.4","spread":"6.68"},{"groupId":"OG002","value":"-144.3","spread":"6.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-156.0","spread":"6.35"},{"groupId":"OG002","value":"-144.2","spread":"6.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-119.8","spread":"7.74"},{"groupId":"OG002","value":"-156.0","spread":"7.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-135.1","spread":"7.01"},{"groupId":"OG002","value":"-155.5","spread":"7.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-155.8","spread":"6.46"},{"groupId":"OG002","value":"-149.7","spread":"6.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-156.9","spread":"6.68"},{"groupId":"OG002","value":"-150.4","spread":"6.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-155.4","spread":"6.56"},{"groupId":"OG002","value":"-163.4","spread":"6.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-162.2","spread":"6.17"},{"groupId":"OG002","value":"-163.3","spread":"6.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-144.2","spread":"6.92"},{"groupId":"OG002","value":"-157.8","spread":"6.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-153.5","spread":"6.52"},{"groupId":"OG002","value":"-158.2","spread":"6.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-156.4","spread":"6.70"},{"groupId":"OG002","value":"-160.7","spread":"6.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-165.5","spread":"6.17"},{"groupId":"OG002","value":"-160.4","spread":"6.21"}]}]}]},{"type":"SECONDARY","title":"Central Subfield Thickness (CSFT) (Micrometers): ANOVA Results for Average Change From Baseline Over the Period Week 88 Through Week 100 for the Study Eye (Full Analysis Set - LOCF)","description":"Central subfield thickness (average thickness of circular 1mm area centered around fovea measured from RPE to ILM, inclusively). Assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nLS Mean estimates are reported, comparing the 2 Brolucizumab arms to Aflibercept. Results do not apply to the Brolucizumab 6 mg arm when Brolucizumab 3mg is compared to Aflibercept. Likewise, results do not apply to the Brolucizumab 3 mg arm when Brolucizumab 6 mg is compared to Aflibercept.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-167.1","spread":"6.54"},{"groupId":"OG002","value":"-168.8","spread":"6.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-171.9","spread":"6.18"},{"groupId":"OG002","value":"-168.5","spread":"6.22"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of Subretinal Fluid (SRF) at Each Assessment Visit","description":"Subretinal Fluid (SRF) status in the central subfield: proportion of subjects with presence of SRF in the study eye by visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of Intraretinal Fluid (IRF) at Each Assessment Visit","description":"Intraretinal Fluid (IRF) status in the central subfield: proportion of subjects with presence of IRF in the study eye by visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"161","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"162","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"150","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"149","spread":null},{"groupId":"OG002","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of SRF and/or IRF in the Study Eye by Visit","description":"Subretinal Fluid (SRF) and Intraretinal Fluid (IRF) status in the central subfield: proportion of subjects with presence of SRF and/or IRF in the study eye by visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"172","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"173","spread":null},{"groupId":"OG002","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"162","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"162","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"150","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"149","spread":null},{"groupId":"OG002","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of Leakage on Fluorescein Angiography (FA) at Week 52","description":"Assessed by angiography.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"140","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of Leakage on Fluorescein Angiography (FA) at Week 100","description":"Assessed by angiography.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Number of Subjects With >=2-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Number of Subjects","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Proportion of Subjects With >=2-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Percentage Estimates","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.\n\n* estimates are reported, comparing the 2 Brolucizumab arms to Aflibercept. Results do not apply to the Brolucizumab 6 mg arm when Brolucizumab 3mg is compared to Aflibercept. Likewise, results do not apply to the Brolucizumab 3 mg arm when Brolucizumab 6 mg is compared to Aflibercept.\n* estimates represent the % of participants who were estimated to have a \"\\>=2-step Improvement From Baseline in the DRSS Score\" from pairwise logistic regression models adjusting for baseline DRSS score categories (\\<=4, ≥5), age categories (\\<65, ≥65 years) and treatment as fixed effect factors.\n\nAbbreviation: Proportion Estimates = P.E.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG002","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"25.8","spread":null},{"groupId":"OG002","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG002","value":"22.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"29.0","spread":null},{"groupId":"OG002","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG002","value":"28.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"29.0","spread":null},{"groupId":"OG002","value":"28.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG002","value":"30.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"32.1","spread":null},{"groupId":"OG002","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Number of Subjects With >=3-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Number of Subjects","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Proportion of Subjects With >=3-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Percentage Estimates","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.\n\n* estimates are reported, comparing the 2 Brolucizumab arms to Aflibercept. Results do not apply to the Brolucizumab 6 mg arm when Brolucizumab 3mg is compared to Aflibercept. Likewise, results do not apply to the Brolucizumab 3 mg arm when Brolucizumab 6 mg is compared to Aflibercept.\n* estimates represent the % of participants who were estimated to have a \"\\>=3-step Improvement From Baseline in the DRSS Score\" from pairwise logistic regression models adjusting for baseline DRSS score categories (\\<=4, ≥5), age categories (\\<65, ≥65 years) and treatment as fixed effect factors.\n\nAbbreviation: Proportion Estimates = P.E.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG002","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"16.8","spread":null},{"groupId":"OG002","value":"12.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG002","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"20.5","spread":null},{"groupId":"OG002","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG002","value":"23.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"21.1","spread":null},{"groupId":"OG002","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG002","value":"22.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"23.2","spread":null},{"groupId":"OG002","value":"22.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Composite Score","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"11.89"},{"groupId":"OG001","value":"6.0","spread":"14.27"},{"groupId":"OG002","value":"7.8","spread":"12.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"12.89"},{"groupId":"OG001","value":"6.7","spread":"13.24"},{"groupId":"OG002","value":"8.5","spread":"12.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"13.21"},{"groupId":"OG001","value":"5.8","spread":"14.50"},{"groupId":"OG002","value":"7.1","spread":"12.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"15.16"},{"groupId":"OG001","value":"6.5","spread":"14.41"},{"groupId":"OG002","value":"6.2","spread":"13.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - General Vision","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"14.75"},{"groupId":"OG001","value":"10.8","spread":"18.11"},{"groupId":"OG002","value":"11.3","spread":"15.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"14.74"},{"groupId":"OG001","value":"11.2","spread":"17.18"},{"groupId":"OG002","value":"10.7","spread":"17.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"14.89"},{"groupId":"OG001","value":"10.0","spread":"17.80"},{"groupId":"OG002","value":"11.7","spread":"17.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"17.87"},{"groupId":"OG001","value":"13.5","spread":"17.97"},{"groupId":"OG002","value":"11.5","spread":"16.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Ocular Pain","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"21.02"},{"groupId":"OG001","value":"2.4","spread":"21.92"},{"groupId":"OG002","value":"4.3","spread":"23.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"19.55"},{"groupId":"OG001","value":"4.9","spread":"19.54"},{"groupId":"OG002","value":"5.3","spread":"22.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"19.75"},{"groupId":"OG001","value":"2.1","spread":"22.78"},{"groupId":"OG002","value":"3.9","spread":"21.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"19.90"},{"groupId":"OG001","value":"3.1","spread":"18.37"},{"groupId":"OG002","value":"2.0","spread":"19.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Near Activities","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"19.83"},{"groupId":"OG001","value":"13.2","spread":"24.93"},{"groupId":"OG002","value":"13.7","spread":"20.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"21.41"},{"groupId":"OG001","value":"14.1","spread":"24.17"},{"groupId":"OG002","value":"13.4","spread":"23.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"20.00"},{"groupId":"OG001","value":"14.9","spread":"23.35"},{"groupId":"OG002","value":"12.4","spread":"20.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"22.23"},{"groupId":"OG001","value":"15.7","spread":"22.01"},{"groupId":"OG002","value":"10.4","spread":"23.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Distance Activities","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"18.39"},{"groupId":"OG001","value":"7.9","spread":"21.58"},{"groupId":"OG002","value":"9.0","spread":"19.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"22.20"},{"groupId":"OG001","value":"9.0","spread":"19.42"},{"groupId":"OG002","value":"9.9","spread":"20.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"20.45"},{"groupId":"OG001","value":"8.1","spread":"19.20"},{"groupId":"OG002","value":"7.0","spread":"18.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"20.68"},{"groupId":"OG001","value":"7.0","spread":"19.24"},{"groupId":"OG002","value":"6.7","spread":"19.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Social Functioning","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"17.79"},{"groupId":"OG001","value":"2.2","spread":"18.00"},{"groupId":"OG002","value":"3.9","spread":"14.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"18.82"},{"groupId":"OG001","value":"2.7","spread":"17.53"},{"groupId":"OG002","value":"3.8","spread":"15.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"17.24"},{"groupId":"OG001","value":"0.5","spread":"18.95"},{"groupId":"OG002","value":"1.7","spread":"16.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"19.68"},{"groupId":"OG001","value":"2.0","spread":"21.82"},{"groupId":"OG002","value":"1.4","spread":"16.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Mental Health","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"20.63"},{"groupId":"OG001","value":"8.2","spread":"22.21"},{"groupId":"OG002","value":"8.7","spread":"19.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"22.93"},{"groupId":"OG001","value":"9.6","spread":"21.42"},{"groupId":"OG002","value":"11.3","spread":"21.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"21.07"},{"groupId":"OG001","value":"11.5","spread":"21.10"},{"groupId":"OG002","value":"11.2","spread":"20.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"25.28"},{"groupId":"OG001","value":"9.4","spread":"23.62"},{"groupId":"OG002","value":"10.9","spread":"22.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Role Difficulties","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"24.93"},{"groupId":"OG001","value":"6.5","spread":"26.81"},{"groupId":"OG002","value":"9.4","spread":"27.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"23.88"},{"groupId":"OG001","value":"6.1","spread":"29.11"},{"groupId":"OG002","value":"11.3","spread":"25.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"25.10"},{"groupId":"OG001","value":"6.8","spread":"29.48"},{"groupId":"OG002","value":"7.4","spread":"27.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"28.27"},{"groupId":"OG001","value":"9.6","spread":"28.88"},{"groupId":"OG002","value":"6.9","spread":"26.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Dependency","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"21.80"},{"groupId":"OG001","value":"6.1","spread":"25.16"},{"groupId":"OG002","value":"7.1","spread":"22.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"23.05"},{"groupId":"OG001","value":"4.1","spread":"25.36"},{"groupId":"OG002","value":"9.0","spread":"22.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"22.93"},{"groupId":"OG001","value":"4.2","spread":"25.56"},{"groupId":"OG002","value":"6.8","spread":"22.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"24.89"},{"groupId":"OG001","value":"3.2","spread":"25.79"},{"groupId":"OG002","value":"5.6","spread":"25.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Driving","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"16.40"},{"groupId":"OG001","value":"1.9","spread":"17.74"},{"groupId":"OG002","value":"6.7","spread":"15.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"16.51"},{"groupId":"OG001","value":"3.6","spread":"18.73"},{"groupId":"OG002","value":"6.4","spread":"17.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"16.09"},{"groupId":"OG001","value":"2.9","spread":"18.34"},{"groupId":"OG002","value":"6.5","spread":"19.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"16.58"},{"groupId":"OG001","value":"4.3","spread":"20.24"},{"groupId":"OG002","value":"2.3","spread":"18.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Color Vision","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"14.37"},{"groupId":"OG001","value":"2.6","spread":"18.20"},{"groupId":"OG002","value":"1.8","spread":"14.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"16.11"},{"groupId":"OG001","value":"2.0","spread":"12.59"},{"groupId":"OG002","value":"1.6","spread":"15.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"13.58"},{"groupId":"OG001","value":"0.2","spread":"17.01"},{"groupId":"OG002","value":"0.2","spread":"13.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"14.14"},{"groupId":"OG001","value":"1.3","spread":"15.79"},{"groupId":"OG002","value":"0.5","spread":"16.94"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - Peripheral Vision","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"20.89"},{"groupId":"OG001","value":"1.6","spread":"22.05"},{"groupId":"OG002","value":"9.2","spread":"22.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"22.51"},{"groupId":"OG001","value":"4.1","spread":"22.97"},{"groupId":"OG002","value":"8.5","spread":"22.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"21.01"},{"groupId":"OG001","value":"1.1","spread":"24.33"},{"groupId":"OG002","value":"7.3","spread":"20.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"21.87"},{"groupId":"OG001","value":"-0.4","spread":"24.36"},{"groupId":"OG002","value":"6.3","spread":"24.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Visual Functioning Questionnaire-25 (VFQ-25) Total Scores up to Week 52 and Week 100 - General Health Rating","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"19.50"},{"groupId":"OG001","value":"3.0","spread":"22.10"},{"groupId":"OG002","value":"6.1","spread":"19.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"22.50"},{"groupId":"OG001","value":"6.8","spread":"22.32"},{"groupId":"OG002","value":"6.8","spread":"24.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"23.53"},{"groupId":"OG001","value":"6.3","spread":"24.18"},{"groupId":"OG002","value":"8.2","spread":"20.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"23.97"},{"groupId":"OG001","value":"6.9","spread":"23.55"},{"groupId":"OG002","value":"8.8","spread":"21.72"}]}]}]},{"type":"SECONDARY","title":"Ocular Adverse Events (AEs) (>=2% in Any Treatment Arm) by Preferred Term for the Study Eye","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Non-ocular Adverse Events (AEs) (>=2% in Any Treatment Arm)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"143","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":190},"commonTop":["Hypertension","Conjunctival haemorrhage - Study eye","Nasopharyngitis","Urinary tract infection","Diabetic retinal oedema - Fellow eye"]}}}